86 133

Cited 0 times in

Clinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006)

DC Field Value Language
dc.contributor.author안성귀-
dc.contributor.author정준-
dc.contributor.author정준-
dc.date.accessioned2021-09-29T00:59:27Z-
dc.date.available2021-09-29T00:59:27Z-
dc.date.issued2021-04-
dc.identifier.issn1738-6756-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/184136-
dc.description.abstractPurpose: In this trial, we investigated the efficacy and safety of adjuvant letrozole for hormone receptor (HR)-positive breast cancer. Here, we report the clinical outcome in postmenopausal women with HR-positive breast cancer treated with adjuvant letrozole according to estrogen receptor (ER) expression levels. Methods: In this multi-institutional, open-label, observational study, postmenopausal patients with HR-positive breast cancer received adjuvant letrozole (2.5 mg/daily) for 5 years unless they experienced disease progression or unacceptable toxicity or withdrew their consent. The patients were stratified into the following 3 groups according to ER expression levels using a modified Allred score (AS): low, intermediate, and high (AS 3-4, 5-6, and 7-8, respectively). ER expression was centrally reviewed. The primary objective was the 5-year disease-free survival (DFS) rate. Results: Between April 25, 2010, and February 5, 2014, 440 patients were enrolled. With a median follow-up of 62.0 months, the 5-year DFS rate in all patients was 94.2% (95% confidence interval [CI], 91.8-96.6). The 5-year DFS and recurrence-free survival (RFS) rates did not differ according to ER expression; the 5-year DFS rates were 94.3% and 94.1%in the low-to-intermediate and high expression groups, respectively (p = 0.6), and the corresponding 5-year RFS rates were 95.7% and 95.4%, respectively (p = 0.7). Furthermore, 25 patients discontinued letrozole because of drug toxicity. Conclusion: Treatment with adjuvant letrozole showed very favorable treatment outcomes and good tolerability among Korean postmenopausal women with ER-positive breast cancer, independent of ER expression. Trial registration: ClinicalTrials.gov Identifier: NCT01069211.-
dc.description.statementOfResponsibilityopen-
dc.languageKorean, English-
dc.publisherKorean Breast Cancer Society-
dc.relation.isPartOfJOURNAL OF BREAST CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleClinical Outcomes Following Letrozole Treatment according to Estrogen Receptor Expression in Postmenopausal Women: LETTER Study (KBCSG-006)-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학교실)-
dc.contributor.googleauthorSung Gwe Ahn-
dc.contributor.googleauthorSeok Jin Nam-
dc.contributor.googleauthorSei Hyun Ahn-
dc.contributor.googleauthorYongsik Jung-
dc.contributor.googleauthorHeung Kyu Park-
dc.contributor.googleauthorSoo Jung Lee-
dc.contributor.googleauthorSung Soo Kang-
dc.contributor.googleauthorWonshik Han-
dc.contributor.googleauthorKyong Hwa Park-
dc.contributor.googleauthorYong Lai Park-
dc.contributor.googleauthorJihyoun Lee-
dc.contributor.googleauthorHyun Jo Youn-
dc.contributor.googleauthorJun Hyun Kim-
dc.contributor.googleauthorYoungbum Yoo-
dc.contributor.googleauthorJeong Yoon Song-
dc.contributor.googleauthorByung Kyun Ko-
dc.contributor.googleauthorGeumhee Gwak-
dc.contributor.googleauthorMin Sung Chung-
dc.contributor.googleauthorSung Yong Kim-
dc.contributor.googleauthorSeo Heon Cho-
dc.contributor.googleauthorDoyil Kim-
dc.contributor.googleauthorMyung Chul Chang-
dc.contributor.googleauthorByung In Moon-
dc.contributor.googleauthorLee Su Kim-
dc.contributor.googleauthorSei Joong Kim-
dc.contributor.googleauthorMin Ho Park-
dc.contributor.googleauthorTae Hyun Kim-
dc.contributor.googleauthorJihyoung Cho-
dc.contributor.googleauthorCheol Wan Lim-
dc.contributor.googleauthorYoung Tae Bae-
dc.contributor.googleauthorGyungyub Gong-
dc.contributor.googleauthorYoung Kyung Bae-
dc.contributor.googleauthorAhwon Lee-
dc.contributor.googleauthorJoon Jeong-
dc.identifier.doi10.4048/jbc.2021.24.e17-
dc.contributor.localIdA02231-
dc.contributor.localIdA03727-
dc.contributor.localIdA03727-
dc.relation.journalcodeJ01279-
dc.identifier.eissn2092-9900-
dc.identifier.pmid33818022-
dc.subject.keywordBreast neoplasms-
dc.subject.keywordLetrozole-
dc.subject.keywordPostmenopause-
dc.subject.keywordReceptors, estrogen-
dc.contributor.alternativeNameAhn, Sung Gwe-
dc.contributor.affiliatedAuthor안성귀-
dc.contributor.affiliatedAuthor정준-
dc.contributor.affiliatedAuthor정준-
dc.citation.volume24-
dc.citation.number2-
dc.citation.startPage164-
dc.citation.endPage174-
dc.identifier.bibliographicCitationJOURNAL OF BREAST CANCER, Vol.24(2) : 164-174, 2021-04-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.